These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26033220)

  • 1. Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial.
    Karam JA; Devine CE; Fellman BM; Urbauer DL; Abel EJ; Allaf ME; Bex A; Lane BR; Thompson RH; Wood CG
    BJU Int; 2016 Apr; 117(4):629-35. PubMed ID: 26033220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study.
    Lebacle C; Bensalah K; Bernhard JC; Albiges L; Laguerre B; Gross-Goupil M; Baumert H; Lang H; Tricard T; Duclos B; Arnoux A; Piedvache C; Patard JJ; Escudier B
    BJU Int; 2019 May; 123(5):804-810. PubMed ID: 30288884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy.
    Hakimi K; Campbell SC; Nguyen MV; Rathi N; Wang L; Meagher MF; Rini BI; Ornstein M; McKay RR; Derweesh IH
    BJU Int; 2024 Apr; 133(4):425-431. PubMed ID: 37916303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
    Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
    Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney cancer: progress and controversies in neoadjuvant therapy.
    Posadas EM; Figlin RA
    Nat Rev Urol; 2014 May; 11(5):254-5. PubMed ID: 24752207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
    Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma.
    Chéry L; Borregales LD; Fellman B; Urbauer DL; Garg N; Parker N; Katz MHG; Wood CG; Karam JA
    Urology; 2017 Oct; 108():114-121. PubMed ID: 28705573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the Kidney Tumor-Parenchymal Interface after Neoadjuvant Treatment with Axitinib for Locally Advanced Clear Cell Renal Cell Carcinoma: Matched Analysis from a Phase II Trial.
    Kawakami F; Rao P; Tamboli P; Wood CG; Karam JA
    J Urol; 2017 Mar; 197(3 Pt 1):559-565. PubMed ID: 27678298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava.
    Tanaka Y; Hatakeyama S; Hosogoe S; Tanaka T; Hamano I; Kusaka A; Iwamura H; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
    Int J Clin Oncol; 2018 Feb; 23(1):134-141. PubMed ID: 28752352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis.
    McDonald ML; Lane BR; Jimenez J; Lee HJ; Yim K; Bindayi A; Hamilton ZA; Field CA; Bloch AS; Dey S; Noyes S; McKay R; Millard F; Rini BI; Campbell SC; Derweesh IH
    Clin Genitourin Cancer; 2018 Apr; 16(2):e289-e295. PubMed ID: 29113767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report.
    Koie T; Ohyama C; Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y
    BMC Res Notes; 2013 Nov; 6():484. PubMed ID: 24267160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial.
    Huang J; Wang Y; Xu F; Wang Z; Wu G; Kong W; Cheoklong NG; Tricard T; Wu X; Zhai W; Zhang W; Zhang J; Zhang D; Chen S; Lian Y; Chen Y; Zhang J; Huang Y; Xue W
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38862251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
    Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
    Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma.
    Rini BI; Plimack ER; Takagi T; Elson P; Wood LS; Dreicer R; Gilligan T; Garcia J; Zhang Z; Kaouk J; Krishnamurthi V; Stephenson AJ; Fergany A; Klein EA; Uzzo RG; Chen DY; Campbell SC
    J Urol; 2015 Aug; 194(2):297-303. PubMed ID: 25813447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma.
    Greco F; Mirone V
    Eur Urol; 2015 Aug; 68(2):336. PubMed ID: 26149726
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively.
    Broughton GJ; Clark PE; Barocas DA; Cookson MS; Smith JA; Herrell SD; Chang SS
    BJU Int; 2012 Jun; 109(11):1607-13. PubMed ID: 21939493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma.
    Sassa N; Kato M; Funahashi Y; Maeda M; Inoue S; Gotoh M
    Jpn J Clin Oncol; 2014 Apr; 44(4):370-3. PubMed ID: 24571808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.